Video: No Evidence That AREDS Vitamins Slow GA Progression - Summary - MDSpire

Video: No Evidence That AREDS Vitamins Slow GA Progression

A post hoc analysis of OAKS and DERBY data failed to support the foveal protection suggested by an earlier AREDS study.

  • By

  • Paul Hahn, MD, PhD

  • July 14, 2025

  • 4 min

Share

Objective:

To evaluate the impact of AREDS vitamin supplements on the progression of geographic atrophy (GA) using data from the OAKS and DERBY trials, which are pivotal studies in this area.

Approach:
    Key Findings:
    • No significant effect of AREDS or AREDS2 vitamin supplementation on GA growth or vision loss was found, failing to reproduce earlier reported benefits.
    • The previously reported benefit of slowing GA growth towards the fovea was not reproduced in this analysis.
    • AREDS vitamins did not augment the effects of pegcetacoplan on GA growth or influence the development of exudative AMD.
    Interpretation:

    The findings suggest that AREDS vitamins do not provide meaningful benefits in slowing the progression of geographic atrophy, contradicting earlier studies and indicating a need for further research into effective treatments.

    Limitations:
    • The analysis was a post hoc study, which may limit the strength of the conclusions drawn from the data.
    • Differences in patient populations and imaging techniques between studies may affect comparability and the generalizability of the findings.
    Conclusion:

    Further research is needed to explore effective treatments for geographic atrophy, as current evidence does not support the use of AREDS vitamins, highlighting the necessity for alternative therapeutic strategies.

Original Source(s)

Video: No Evidence That AREDS Vitamins Slow GA Progression

  • by Paul Hahn, MD, PhD

  • July 14, 2025

Related Content

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min
The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it. 

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.